| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Dr. Reddy's Laboratories Limited (NYSE: RDY)
RDY Technical Analysis
1.5
| As on 9th Jun 2023 RDY SHARE Price closed @ 57.23 and we RECOMMEND Buy for LONG-TERM with Stoploss of 55.01 & Sell for SHORT-TERM with Stoploss of 58.64 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RDYSHARE Price
| Open | 56.79 | Change | Price | % |
| High | 57.25 | 1 Day | 0.24 | 0.42 |
| Low | 56.45 | 1 Week | 2.04 | 3.70 |
| Close | 57.23 | 1 Month | -3.35 | -5.53 |
| Volume | 127500 | 1 Year | -4.36 | -7.08 |
| 52 Week High 65.42 | 52 Week Low 48.27 | ||||
NYSE USA Most Active Stocks
| DDR | 15.44 | -4.46% |
| NIO | 7.73 | -0.77% |
| TWTR | 53.70 | 0.66% |
| CVNA | 19.07 | -21.30% |
| BACA-U | 302.00 | 0.67% |
| PLTR | 15.02 | -1.12% |
| F | 13.74 | 1.18% |
| CS | 0.89 | 1.14% |
| RPAI | 13.15 | -3.17% |
| AUY | 5.85 | -0.68% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| RDY Daily Charts |
RDY Intraday Charts |
Whats New @ Bazaartrend |
RDY Free Analysis |
|
|
RDY Important Levels Intraday
| RESISTANCE | 58.77 |
| RESISTANCE | 58.28 |
| RESISTANCE | 57.97 |
| RESISTANCE | 57.67 |
| SUPPORT | 56.79 |
| SUPPORT | 56.49 |
| SUPPORT | 56.18 |
| SUPPORT | 55.69 |
RDY Forecast April 2024
| 4th UP Forecast | 76.06 |
| 3rd UP Forecast | 70.02 |
| 2nd UP Forecast | 66.29 |
| 1st UP Forecast | 62.55 |
| 1st DOWN Forecast | 51.91 |
| 2nd DOWN Forecast | 48.17 |
| 3rd DOWN Forecast | 44.44 |
| 4th DOWN Forecast | 38.4 |
RDY Weekly Forecast
| 4th UP Forecast | 62.34 |
| 3rd UP Forecast | 60.70 |
| 2nd UP Forecast | 59.69 |
| 1st UP Forecast | 58.67 |
| 1st DOWN Forecast | 55.79 |
| 2nd DOWN Forecast | 54.77 |
| 3rd DOWN Forecast | 53.76 |
| 4th DOWN Forecast | 52.12 |
RDY Forecast2024
| 4th UP Forecast | 91.88 |
| 3rd UP Forecast | 80.77 |
| 2nd UP Forecast | 73.9 |
| 1st UP Forecast | 67.03 |
| 1st DOWN Forecast | 47.43 |
| 2nd DOWN Forecast | 40.56 |
| 3rd DOWN Forecast | 33.69 |
| 4th DOWN Forecast | 22.58 |
Dr. Reddy's Laboratories Limited ( NYSE USA Symbol : RDY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RDY Business Profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Address: 8-2-337, Road No. 3, Hyderabad, India, 500034
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service